Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RUNX1 | Q01196 | 7/20 | 0.56 |
| ▸ | CBFB | Q13951 | 3/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.56 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | GMNN | O75496 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2108293 | 0.87 | RUNX1 (0.43) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL9456207 | 0.86 | TRPV1 (0.54) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL10751918 | 0.83 | TRPV1 (0.45) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL18190875 | 0.81 | RUNX1 (0.56) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL5807305 | 0.81 | RUNX1 (0.56) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL5807225 | 0.81 | SCN10A (0.56) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL32674484 | 0.81 | RUNX1 (0.56) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL9674405 | 0.81 | KDM4E (0.58) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL13219327 | 0.81 | RUNX1 (0.56) | RUNX1CBFBTRPV1SCN10APDE10A | |
| SCHEMBL10146526 | 0.81 | TRPV1 (0.59) | RUNX1CBFBTRPV1SCN10APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-3565586-B1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS INC (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | LION BIOTECHNOLOGIES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | LION BIOTECHNOLOGIES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-11357841-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-11357841-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-02-13 | — | — | US | disclosed |
| EP-3565586-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | Iovance Biotherapeutics, Inc. (US) | 2019-11-13 | — | — | EP | disclosed |
| US-20180291035-A1 | MYC MODULATORS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-10-11 | — | — | US | disclosed |
| WO-2018129336-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2018-07-12 | — | — | WO | disclosed |
| US-10017520-B2 | Myc modulators and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-07-10 | — | — | US | disclosed |
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-16 | — | — | US | disclosed |
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | UNIVERSITY OF IOWA RESEARCH FOUNDATION | 2016-04-28 | — | — | US | disclosed |
| WO-2014160405-A1 | COMPOUNDS, COMPOSITIONS COMPRISING SAME, AND METHODS RELATED THERETO | UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) | 2014-10-02 | — | — | WO | disclosed |
| US-8163768-B2 | 4-(4-Hydroxy-3-methyl-phenyl)-2,4,6,7,8,9-hexahydro-pyrazolo[3,4-b]-1,7-naphthyridin-5-one; inhibiting Aurora kinase; inhibiting the proliferation of tumor cells; cancer, psoriasis, leukaemia and lupus | AVENTIS PHARMA S.A.. (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-1910366-B1 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2011-08-24 | — | — | EP | disclosed |
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | AVENTIS PHARMA S.A. (FR) | 2008-10-23 | — | — | US | disclosed |
| EP-1910366-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007012972-A2 | 1,4-DIHYDROPYRIDINE-FUSED HETEROCYCLES, PROCESS FOR PREPARING THE SAME, USE AND COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 2007-02-01 | — | — | WO | disclosed |
| WO-2006050148-A2 | PROPARGYL TRIFLUOROMETHOXY AMINOBENZIMIDAZOLE DERIVATIVES | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168165-A1 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | RUNX1 777/4885CBFB 257/4885TRPV1 4883/4885 |
| US-20080261969-A1 | 1,4-Dihydropyridine-Fused Heterocycles, Process for Preparing the Same, Use and Compositions Containing Them | DPYD, DHPS, QDPR | RUNX1 907/4885CBFB 3043/4885TRPV1 540/4885 |
| US-20230210966-A1 | EXPANSION OF TUMOR INFILTRATING LYMPHOCYTES WITH POTASSIUM CHANNEL AGONISTS AND THERAPEUTIC USES THEREOF | KCNN3, KCNK3, KCNA3 | RUNX1 1158/4885CBFB 2740/4885TRPV1 102/4885 |
| US-20200048276-A9 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | RUNX1 777/4885CBFB 257/4885TRPV1 4883/4885 |
| US-20160115136-A1 | COMPOUNDS, COMPOSITIONS COMPRSING SAME, AND METHODS RELATED THERETO | LPO, NOTUM, FARS2 | RUNX1 3660/4885CBFB 3419/4885TRPV1 392/4885 |
| US-12629356-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | PBK, IL2, KCNN3 | RUNX1 867/4885CBFB 1826/4885TRPV1 68/4885 |
| US-20180291035-A1 | MYC MODULATORS AND USES THEREOF | MYC, MYCBP, MYCBP2 | RUNX1 777/4885CBFB 257/4885TRPV1 4883/4885 |
| US-10017520-B2 | Myc modulators and uses thereof | MYC, MYCBP, MYCBP2 | RUNX1 777/4885CBFB 257/4885TRPV1 4883/4885 |
| US-11357841-B2 | Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof | KCNN3, KCNK3, KCNA3 | RUNX1 1158/4885CBFB 2740/4885TRPV1 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.